CVS to Pay $315 Million to Resolve DOJ Opioid Prescription Lawsuit
CVS Health agreed to pay $315 million to settle a Justice Department lawsuit over allegedly invalid opioid prescriptions filled by its pharmacies. The company denied wrongdoing, and the payment is small compared with its operating cash flow. CVS shares were little changed, with investors more focused on the company's 2027 earnings guidance and an upcoming quarterly call.
CVS Health reached the $315 million settlement on October 13. The government claimed its pharmacies dispensed invalid opioid and controlled-substance prescriptions between October 2013 and December 2025 and sought reimbursement from Medicare and other federal programs. CVS denied liability. The agreement also requires a reporting hotline, dispensing-pattern monitoring, and a DEA process for reviewing suspect prescribers.
CVS generated $10.64 billion from operations in 2025 and expects at least $11.5 billion this year; the payment equals under 3% of either figure, or roughly 25 cents per share. It follows a separate Omnicare settlement worth at least $440 million, while Walmart resolved a similar DOJ case for $50 million in August.
The settlement could affect patients, pharmacies, and communities touched by opioid prescribing. It may reinforce compliance efforts, including prescription monitoring and reporting channels, potentially making some patients face extra scrutiny when filling controlled substances. Taxpayers and federal health programs may see some recovery, though the amount is small relative to CVS’s cash flow. The outcome may matter